parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.03 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocyte progenitor cells; strongest in pancreatic islet cells	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	5 Parkinson's papers of 83	0.76
pathways Reactome	3 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 7037

receipt 7045: SCG3 in dopamine neurons, braak

power: full sample +0.17 (p 0.498, n 18), 95% CI -0.32 to +0.59. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.12 (p 0.627, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.14 (p 0.579, n 18). could be the mix.
skeptic: leave-one-out range +0.09 to +0.30, sign flips 0; without severely affected donors +0.17 (p 0.498, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for SCG3 in dopamine neurons.

case closed: nothing better to follow up.

receipt 7044: SCG3 in oligodendrocytes, braak

power: full sample +0.13 (p 0.609, n 18), 95% CI -0.36 to +0.56. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.19 (p 0.455, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.18 (p 0.487, n 18). could be the mix.
skeptic: leave-one-out range +0.02 to +0.27, sign flips 0; without severely affected donors +0.13 (p 0.609, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for SCG3 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts